LENZ Therapeutics' stock surged 13% in premarket trading after successful Phase 3 trial results for its presbyopia treatment in China. The study showed significant improvement in visual acuity, with positive safety and efficacy outcomes.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing